title: [The case of Vioxx requires consideration].
authors.affiliation: Krokoms hälsocentral, Krokom. jan.hakansson@jll.se
authors.forename: Jan
authors.initials: J
authors.lastname: Håkansson
authors.forename: Peter
authors.initials: P
authors.lastname: Rosenberg
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced; D004345:Drug Industry; D004346:Drug Information Services; D004335:Drug and Narcotic Control; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D040541:Marketing; D012307:Risk Factors; D013450:Sulfones
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib